Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939907 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRHPGDHTR2CFABP7 | |
| SCHEMBL18717597 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRHPGDHTR2CFABP7 | |
| SCHEMBL19916988 | 0.93 | TSHR (0.47) | ALDH1A1TSHRHPGDHTR2CFABP7 | |
| SCHEMBL17390977 | 0.90 | ALDH1A1 (0.60) | ALDH1A1TSHRHPGDFABP7FABP5 | |
| SCHEMBL17391194 | 0.90 | ALDH1A1 (0.60) | ALDH1A1TSHRHPGDFABP7FABP5 | |
| SCHEMBL17390980 | 0.90 | ALDH1A1 (0.60) | ALDH1A1TSHRHPGDFABP7FABP5 | |
| SCHEMBL9002126 | 0.90 | ALDH1A1 (0.60) | ALDH1A1TSHRHPGDFABP7FABP5 | |
| SCHEMBL16216073 | 0.89 | TSHR (0.52) | ALDH1A1TSHRHPGDHTR2CFABP7 | |
| SCHEMBL10292295 | 0.89 | TSHR (0.52) | ALDH1A1TSHRHPGDHTR2CFABP7 | |
| SCHEMBL13634275 | 0.89 | TSHR (0.52) | ALDH1A1TSHRHPGDHTR2CFABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2022108507-A1 | Chemoselective probes and uses thereof | LIN WEIFENG (SE) | 2022-05-27 | — | — | WO | disclosed |
| CN-109568321-B | ROR gamma modulators | 山东轩竹医药科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.à.r.l. (LU) | 2019-04-16 | — | — | US | disclosed |
| US-9969736-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9079913-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140378680-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-25 | — | — | US | disclosed |
| US-8877796-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8680132-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130296303-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| US-8518984-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2013004828-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-C]PYRIDINE RING | SANOFI (FR) | 2013-01-10 | — | — | WO | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378680-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | ALDH1A1 1498/4885TSHR 2230/4885HPGD 677/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | ALDH1A1 3177/4885TSHR 230/4885HPGD 1770/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | ALDH1A1 3001/4885TSHR 210/4885HPGD 1702/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | ALDH1A1 3177/4885TSHR 230/4885HPGD 1770/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | ALDH1A1 793/4885TSHR 1514/4885HPGD 539/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | ALDH1A1 542/4885TSHR 2764/4885HPGD 117/4885 |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885TSHR 4540/4885HPGD 1050/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | ALDH1A1 3734/4885TSHR 411/4885HPGD 1811/4885 |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, P2RY1, P2RX5 | ALDH1A1 3001/4885TSHR 210/4885HPGD 1702/4885 |
| US-20130296303-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | ALDH1A1 1498/4885TSHR 2230/4885HPGD 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.